<DOC>
	<DOCNO>NCT02728947</DOCNO>
	<brief_summary>To study profile Neupro patch administrate 2 mg , 4 mg , 6 mg 8 mg/day weekly patient early-stage Parkinson 's disease</brief_summary>
	<brief_title>Pharmacokinetic Profile Neupro Patch Administrated 2 mg , 4 mg , 6 mg 8 mg/Day Weekly Patients With Early-stage Parkinson 's Disease</brief_title>
	<detailed_description>A single group open-label study evaluate pharmacokinetic profile Neupro patch administrate 2 mg , 4 mg , 6 mg 8 mg/day weekly patient early-stage Parkinson 's disease</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>1 . Patient capable give informed consent comply study procedure 2 . Patient Idiopathic Parkinson 's Disease define cardinal sign , bradykinesia , plus presence least 1 follow : rest tremor , rigidity , impairment postural reflex , without know suspected cause Parkinsonism 3 . Patient Hoehn &amp; Yahr stage less equal 3 4 . Patient male female age great equal 18 year Screening 5 . Patient Mini Mental State Examination ( MMSE ) score great equal 25 6 . Patient Unified Parkinson 's Disease Rating Scale ( UPDRS ) motor score ( Part III ) great equal 10 less equal 30 Screening 1 . Patient atypical Parkinson 's syndrome ( ) due drug ( e.g. , metoclopramide , flunarizine ) , metabolic neurogenetic disorder ( e.g. , Wilson 's Disease ) , encephalitis , cerebrovascular disease , degenerative disease ( e.g. , progressive Supranuclear Palsy ) 2 . Patient history pallidotomy , thalamotomy , deep brain stimulation , fetal tissue transplant 3 . Patient dementia , active psychosis hallucination , clinically significant depression 4 . Patient lifetime history suicide attempt ( include active attempt , interrupt attempt , aborted attempt ) , suicidal ideation past 6 month indicate positive response ( `` Yes '' ) either Question 4 Question 5 ColumbiaSuicide Severity Rating Scale ( CSSRS ) Screening 5 . Patient history symptomatic orthostatic hypotension decrease less equal 20 mmHg systolic blood pressure ( SBP ) great equal 10 mmHg diastolic blood pressure change supine stand position supine position least 5 minute within 28 day prior Screening Visit , SBP le 105 mmHg study entry , report clinical sign clinically significant orthostatic hypotension within 28 day prior Screening Visit . 6 . Patient receive therapy dopamine agonist either concurrently do within 28 day prior Screening 7 . Patient receive therapy 1 follow drug either concurrently within 28 day prior screen : MAOB inhibitor , DA release agent , DA modulating agent , DA antagonists , neuroleptic , medication may interact DA function . 8 . Patient currently receive central nervous system active therapy ( e.g. , sedative , hypnotic , antidepressant , anxiolytic ) , unless dose stable least 28 day prior Screening Visit likely remain stable duration study . Patients take medication within 8 hour prior clinical visit 9 . Patient current diagnosis epilepsy , history seizure adult , history stroke , transient ischemic attack within 1 year prior Screening 10 . Patient history know intolerance/hypersensitivity nondopaminegic antiemetic , domperidone , ondansetron , tropisetron , glycopyrrolate 11 . Patient clinically relevant hepatic , renal cardiac dysfunction , medical condition laboratory abnormality include abnormal plasma magnesium level , would judgment investigator , interfere patient 's ability participate study 12 . Patient history significant skin hypersensitivity adhesive transdermal preparation recent unresolved contact Dermatitis 13 . Patient Creactive protein level 2x upper limit normal range 14 . Female patient pregnant breastfeed childbearing potential without adequate contraception . 15 . Patient positive find drug screen test alcohol test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Parkinson 's Disease</keyword>
</DOC>